Clinical Trial Detail

NCT ID NCT02965716
Title Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Pembrolizumab + Talimogene laherparepvec

Age Groups: senior adult

No variant requirements are available.